PTC Unveils Arena SCI for Resilient Product Development
PTC Inc. PTC recently introduced a transformative advancement for its Arena PLM (Product Lifecycle Management) and QMS (Quality Management System) solutions — the Arena Supply Chain Intelligence (SCI) offering. The state-of-the-art solution embeds AI-driven component risk monitoring directly into the Arena PLM/QMS environment, enabling real-time visibility and smarter sourcing decisions from the earliest stages of product design.By continuously monitoring electronic components across bills of materials, Arena SCI identifies risks stemming from evolving supply conditions. When a risk is detected, the system flags it and suggests technically compatible alternative parts, empowering teams to make adjustments before issues escalate. These capabilities bolster the way product development teams handle component risks across the entire product lifecycle, seamlessly integrating with their existing PLM systems.Arena SCI is powered by Accuris, a leading source of electronic component data. Accuris ensures that users access the most comprehensive and up-to-date risk and parts information available. This level of detail gives engineers and professionals visibility into their component portfolios, enabling them to make decisions that balance performance, cost and availability.Companies like Universal Audio, which specialize in professional audio hardware, are already reaping the benefits of Arena SCI. This reflects a broader industry trend in which development teams are under pressure to innovate quickly, even as parts become harder to source and supply chains grow more unpredictable.
SCI is part of PTC's broader commitment to transforming the product development landscape through cloud-native solutions. Arena's integration with Onshape, PTC's cloud-native computer-aided design (CAD) and product data management (PDM) platform, has already laid the foundation for seamless cross-functional collaboration. With Arena SCI, PTC now offers the industry's first cloud-native CAD-PDM-PLM-Supply Chain solution, minimizing the usual challenges, expenses and custom coding required to link design and development systems.Recently, the company introduced model-based definition (MBD) capabilities within its Onshape platform—a fully cloud-native CAD and PDM solution. This initiative marks the first MBD offering of its kind in a cloud-native environment, designed to streamline product development by embedding product manufacturing information (PMI) directly into 3D models.
Since being acquired by PTC, Arena has accelerated its product roadmap with more than 16 major product releases, expansion into new global markets and collaboration with dozens of new ecosystem partners. It is trusted by nearly 1,500 global manufacturers, including Nutanix, Insulet, and Enphase Energy. With Arena SCI, PTC is solidifying its position as a digital transformation leader empowering customers to navigate complex, multi-tiered supply chains with ease.As global supply chains continue to evolve, tools like Arena SCI not only mitigate risk but also seize opportunity in a competitive, fast-moving marketplace.Nonetheless, PTC's frequent acquisitions have heightened its integration risks and negatively impacted its balance sheet. As of March 31, 2025, goodwill and acquired intangible assets totaled about $4.3 billion—roughly 70% of its total assets—highlighting the financial strain from acquisitions. These deals have also increased PTC's debt load, raising its overall risk exposure. At the end of the period, the company held $235 million in cash and cash equivalents, while total debt (net of deferred issuance costs) was $1.39 billion. PTC's debt-to-capital ratio is 0.29, notably higher than the industry average of 0.19, signaling elevated financial risk. This underscores the need for PTC to consistently generate sufficient cash flows to cover its debt obligations.
PTC currently carries a Zacks Rank #2 (Buy). Shares of the company have declined 6.6% in the past year against the Zacks Computer-Software industry's growth of 13.8%.
Image Source: Zacks Investment Research
Some other top-ranked stocks from the broader technology space are Juniper Networks, Inc. JNPR, Arista Networks, Inc. ANET and Ubiquiti Inc. UI. JNPR presently sports a Zacks Rank #1 (Strong Buy), while ANET and UI carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Juniper is leveraging the 400-gig cycle to capture hyperscale switching opportunities inside the data center. The company is set to capitalize on the increasing demand for data center virtualization, cloud computing and mobile traffic packet/optical convergence. Juniper also introduced new features within the AI-driven enterprise portfolio that enable customers to simplify the rollout of their campus wired and wireless networks while bringing greater insight to network operators. In the last reported quarter, it delivered an earnings surprise of 4.88%.Arista delivered a trailing four-quarter average earnings surprise of 11.82% and has a long-term growth expectation of 14.81%. Arista currently serves five verticals, namely cloud titans (customers that deploy more than 1 million servers, cloud specialty providers, service providers, financial services and the rest of the enterprise. It supplies products to a prestigious set of customers, including Fortune 500 global companies in markets such as cloud titans, enterprises, financials and specialty cloud service providers.Ubiquiti's effective management of its strong global network of more than 100 distributors and master resellers improved its visibility for future demand and inventory management techniques. In the last reported quarter, Ubiquiti delivered an earnings surprise of 33.3%. Its highly flexible global business model remains well-suited to adapt to the changing market dynamics to overcome challenges while maximizing growth.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Juniper Networks, Inc. (JNPR) : Free Stock Analysis Report
Arista Networks, Inc. (ANET) : Free Stock Analysis Report
PTC Inc. (PTC) : Free Stock Analysis Report
Ubiquiti Inc. (UI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Investing in PTC (NASDAQ:PTC) five years ago would have delivered you a 116% gain
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long term PTC Inc. (NASDAQ:PTC) shareholders would be well aware of this, since the stock is up 116% in five years. We note the stock price is up 1.4% in the last seven days. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, PTC managed to grow its earnings per share at 62% a year. This EPS growth is higher than the 17% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We know that PTC has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts. PTC shareholders are down 6.8% for the year, but the market itself is up 15%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 17%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you would like to research PTC in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 days ago
- Yahoo
PTC Unveils Arena SCI for Resilient Product Development
PTC Inc. PTC recently introduced a transformative advancement for its Arena PLM (Product Lifecycle Management) and QMS (Quality Management System) solutions — the Arena Supply Chain Intelligence (SCI) offering. The state-of-the-art solution embeds AI-driven component risk monitoring directly into the Arena PLM/QMS environment, enabling real-time visibility and smarter sourcing decisions from the earliest stages of product continuously monitoring electronic components across bills of materials, Arena SCI identifies risks stemming from evolving supply conditions. When a risk is detected, the system flags it and suggests technically compatible alternative parts, empowering teams to make adjustments before issues escalate. These capabilities bolster the way product development teams handle component risks across the entire product lifecycle, seamlessly integrating with their existing PLM SCI is powered by Accuris, a leading source of electronic component data. Accuris ensures that users access the most comprehensive and up-to-date risk and parts information available. This level of detail gives engineers and professionals visibility into their component portfolios, enabling them to make decisions that balance performance, cost and like Universal Audio, which specialize in professional audio hardware, are already reaping the benefits of Arena SCI. This reflects a broader industry trend in which development teams are under pressure to innovate quickly, even as parts become harder to source and supply chains grow more unpredictable. SCI is part of PTC's broader commitment to transforming the product development landscape through cloud-native solutions. Arena's integration with Onshape, PTC's cloud-native computer-aided design (CAD) and product data management (PDM) platform, has already laid the foundation for seamless cross-functional collaboration. With Arena SCI, PTC now offers the industry's first cloud-native CAD-PDM-PLM-Supply Chain solution, minimizing the usual challenges, expenses and custom coding required to link design and development the company introduced model-based definition (MBD) capabilities within its Onshape platform—a fully cloud-native CAD and PDM solution. This initiative marks the first MBD offering of its kind in a cloud-native environment, designed to streamline product development by embedding product manufacturing information (PMI) directly into 3D models. Since being acquired by PTC, Arena has accelerated its product roadmap with more than 16 major product releases, expansion into new global markets and collaboration with dozens of new ecosystem partners. It is trusted by nearly 1,500 global manufacturers, including Nutanix, Insulet, and Enphase Energy. With Arena SCI, PTC is solidifying its position as a digital transformation leader empowering customers to navigate complex, multi-tiered supply chains with global supply chains continue to evolve, tools like Arena SCI not only mitigate risk but also seize opportunity in a competitive, fast-moving PTC's frequent acquisitions have heightened its integration risks and negatively impacted its balance sheet. As of March 31, 2025, goodwill and acquired intangible assets totaled about $4.3 billion—roughly 70% of its total assets—highlighting the financial strain from acquisitions. These deals have also increased PTC's debt load, raising its overall risk exposure. At the end of the period, the company held $235 million in cash and cash equivalents, while total debt (net of deferred issuance costs) was $1.39 billion. PTC's debt-to-capital ratio is 0.29, notably higher than the industry average of 0.19, signaling elevated financial risk. This underscores the need for PTC to consistently generate sufficient cash flows to cover its debt obligations. PTC currently carries a Zacks Rank #2 (Buy). Shares of the company have declined 6.6% in the past year against the Zacks Computer-Software industry's growth of 13.8%. Image Source: Zacks Investment Research Some other top-ranked stocks from the broader technology space are Juniper Networks, Inc. JNPR, Arista Networks, Inc. ANET and Ubiquiti Inc. UI. JNPR presently sports a Zacks Rank #1 (Strong Buy), while ANET and UI carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Juniper is leveraging the 400-gig cycle to capture hyperscale switching opportunities inside the data center. The company is set to capitalize on the increasing demand for data center virtualization, cloud computing and mobile traffic packet/optical convergence. Juniper also introduced new features within the AI-driven enterprise portfolio that enable customers to simplify the rollout of their campus wired and wireless networks while bringing greater insight to network operators. In the last reported quarter, it delivered an earnings surprise of 4.88%.Arista delivered a trailing four-quarter average earnings surprise of 11.82% and has a long-term growth expectation of 14.81%. Arista currently serves five verticals, namely cloud titans (customers that deploy more than 1 million servers, cloud specialty providers, service providers, financial services and the rest of the enterprise. It supplies products to a prestigious set of customers, including Fortune 500 global companies in markets such as cloud titans, enterprises, financials and specialty cloud service effective management of its strong global network of more than 100 distributors and master resellers improved its visibility for future demand and inventory management techniques. In the last reported quarter, Ubiquiti delivered an earnings surprise of 33.3%. Its highly flexible global business model remains well-suited to adapt to the changing market dynamics to overcome challenges while maximizing growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Juniper Networks, Inc. (JNPR) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report PTC Inc. (PTC) : Free Stock Analysis Report Ubiquiti Inc. (UI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
2 days ago
- Business Wire
FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today applauded the U.S. Food and Drug Administration's (FDA) approval of Merck's KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test. Merck's application was granted the FDA's priority review on February 25, 2025, and regulatory approval was granted on June 13, 2025, based on interim results from Keytruda's Phase 3 KEYNOTE-689 trial. "The Keytruda approval based on pre-specified interim results strongly implies that Multikine has the potential for accelerated regulatory approval based on favorable post-surgical tumor responses,' stated CEL-SCI's CEO, Geert Kersten. Share Last week the FDA approved Keytruda as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level. In Merck's Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30%, compared with standard of care, in patients whose tumors expressed PD-L1 (CPS ≥1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit from Keytruda. In contrast to the results of the KEYNOTE-689, CEL-SCI's Phase 3 study showed that Multikine* treated patients whose tumors expressed low (Tumor Proportion Score [TPS <10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI's Phase 3 study had low to zero levels of PD-L1. 'It is encouraging for CEL-SCI that Merck's Keytruda application received the FDA's priority review and that marketing approval was given based on a Phase 3 study's first pre-specified interim analysis. CEL-SCI has received the FDA's go-ahead for a confirmatory Registration Study with 212 patients based on results from the completed Multikine Phase 3 study in head and neck cancer patients. The patients in the Phase 3 study that benefited from Multikine pre-surgery treatment showed an almost 4-year median overall survival advantage over control, and pre-surgery tumor responses to Multikine predicted survival benefit. The Keytruda approval based on pre-specified interim results strongly implies that Multikine has the potential for accelerated regulatory approval based on favorable post-surgical tumor responses,' stated CEL-SCI's CEO, Geert Kersten. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study. The study will enroll 212 newly diagnosed locally advanced primary treatment naïve resectable head and neck cancer patients. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
